Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial C
The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design. This study aims to achieve several objectives that contribute to
| Condition(s) | Endometrial Carcinoma (EC) |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design. This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins. |
| Who can participate | Inclusion Criteria: 1. Female sex 2. Age between 50 and 80 years 3. Willingness to participate in the study and signing of the informed consent 4. Clinical condition of post-menopause Exclusion Criteria: 1. Previous hysterectomy 2. Hormone replacement therapy 3. Immunosuppressive therapy |
| Ages | 50 Years to 80 Years |
| Sex | Female |
| Accepts healthy volunteers | Yes |
| Lead sponsor | National Cancer Institute, Naples |
| Locations | Naples, Italy |
| Start date | 2023-07-06 |
| NCT ID | NCT06893861 |
| Official listing | https://clinicaltrials.gov/study/NCT06893861 |